Strong Phase 3 data for Takeda's subcutaneous Entyvio in moderate to severe Crohn's disease

Takeda has shared positive new Phase 3 data on a subcutaneous formulation of its gutselective biologic Entyvio vedolizumab as a maintenance therapy for moderately to severely active Crohn's disease CD in adult patients.The company examined participants who...